Y&R Capital

Y&R Capital, established in May 2015, is a venture capital firm based in Beijing, China, focused on high-tech incubation and service management. It was jointly founded by Zhejiang Ganzhan Investment Management Co., Ltd. and Beijing Bochuang Xingsheng Technology Co., Ltd. The firm emphasizes investment in strategic emerging industries, particularly in the fields of medical health, artificial intelligence, robotics, and intelligent manufacturing. Y&R Capital aims to identify and support innovative companies that exhibit growth potential in these sectors, aligning its investment strategy with the evolving technological landscape.

Ruijun Zhang Ph.D

Founding Partner and CEO

Past deals in Asia

Beijing Weiying Technology

Series A in 2022
Beijing Weiying Technology operates an online movie ticket booking platform known as WePiao, which is integrated within WeChat. The company collaborates with over 2,000 movie theaters across China, including major cinema chains like Wanda. Founded in 2014 by David Lim and headquartered in Beijing, Weiying Technology aims to diversify its offerings by expanding into other entertainment sectors, including online ticket booking for performances and sports events. The platform is designed to enhance user convenience by streamlining the ticket booking process for various events, enabling efficient access to entertainment options.

Arrays Medical Imaging

Series B in 2017
Beijing Arrays Medical Imaging Corporation specializes in the development, production, and sales of advanced medical molecular imaging devices. The company is known for its multi-modality imaging technologies, which are essential for diagnosing cancer, brain, and heart diseases. Its flagship product, the RAYSCAN-64 PET/CT scanner, integrates positron emission tomography (PET) and computed tomography (CT) to deliver high-quality, clear images that enhance disease diagnosis. This innovative device combines the functional imaging capabilities of PET with the anatomical detail provided by CT, achieving performance characteristics comparable to or exceeding those of similar international products. The RAYSCAN-64 PET/CT scanner has undergone clinical validation and has received positive feedback from medical professionals, demonstrating its effectiveness in supporting the diagnostic needs of healthcare practitioners.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.